Amendment AA4-ASA1-AB69

LRBa0106/1

MED:jld

2017 - 2018 LEGISLATURE

ASSEMBLY AMENDMENT 4, TO ASSEMBLY SUBSTITUTE AMENDMENT 1, TO ASSEMBLY BILL 69

March 7, 2017 - Offered by Representatives Subeck, Sargent and Spreitzer.

AB69-ASA1-AA4,1,1 At the locations indicated, amend the substitute amendment as follows:

AB69-ASA1-AA4,1,2 1. Page 3, line 17: after “Manufacturers." insert “(a)".

AB69-ASA1-AA4,1,3 2. Page 3, line 19: after “patient." insert:

AB69-ASA1-AA4,1,4 “(b)".

AB69-ASA1-AA4,1,5 3. Page 3, line 23: after that line insert:

AB69-ASA1-AA4,1,11 “(c) During the time an eligible patient is using an investigational drug, device, or biological product as provided in this section, the manufacturer shall notify the treating physician and the eligible patient of any clinically significant finding of a known or anticipated risk or side effect that is likely related to the investigational drug, device, or biological product that becomes known to the manufacturer after the eligible patient begins using the investigational drug, device, or biological product.”.

AB69-ASA1-AA4,1,12 (End)